MNTA Insider Shareholdings
[Updated for SEC filings through 8/10/10.]
FDA approval of generic Lovenox on 7/23/10 triggered the vesting of
restricted shares held by MNTA’s executive officers, which incurred
an income-tax liability for these officers (#msg-53029172). On MNTA’s
2Q10 CC on 8/3/10, CFO Rick Shea disclosed that some officers would
sell shares to cover their tax liability from the newly vested shares. Since
FDA approval, sales that may be presumed to be tax-related, at least in
part, have been made by Wheeler, Venkataraman, Brugger, and Bishop
at prices between 17.20 and 24.48.
The table entries below include both ordinary and restricted shares
and both vested and non-vested options.
Shares Options
Officers
*Craig Wheeler (CEO) 391,719 675,000
*G Venkataraman‡ (SVP/R&D) 341,990 189,325
*Steven Brugger (COO) 209,779 246,194
*John Bishop (SVP/Pharma) 49,549 121,860
*Richard Shea (CFO) 40,471 249,200
*Bruce Leicher (Gen Cnsl) 38,734 137,050
*James Roach (CMO) 18,032 205,250
Directors
John Clarke 77,123 126,000
†Bruce Downey 0 45,000
Marsha Fanucci 0 126,000
Peter Hutt 67,863 201,500
*Ram Sasisekharan‡ 306,344 126,000
*Bennett Shapiro 7,000 140,450
Elizabeth Stoner 0 79,200
James Sulat (Chairman) 0 60,000
====================== ========= =========
All fifteen insiders 1,548,604 2,728,029
*10b5-1 selling plan in effect.
†Joined BoD 6/11/09.
‡Co-founder.